Nektar Therapeutics (NKTR) Enterprise Value (2011 - 2026)

Nektar Therapeutics' Enterprise Value history runs 17 years deep, the most recent figure standing at -$568.6 million for Q1 2026.

• In Q1 2026, Enterprise Value fell 160.07% year-over-year to -$568.6 million; the TTM figure through Mar 2026 stood at -$568.6 million (down 160.07% YoY), while the FY2025 annual figure was -$245.8 million, up 3.71% from the prior year.
• Enterprise Value for Q1 2026 stood at -$568.6 million, down from -$245.8 million in the prior quarter.
• The five-year high for Enterprise Value was -$175.9 million in Q2 2025, with the low at -$667.0 million in Q1 2022.
• The 5-year median for Enterprise Value is -$303.6 million (2023), against an average of -$377.6 million.
• The sharpest annual moves came in 2022 and 2026: Enterprise Value jumped 40.68% in 2022, then slumped 160.07% in 2026.
• Nektar Therapeutics' Enterprise Value stood at -$505.0 million in 2022, then jumped by 39.88% to -$303.6 million in 2023, then climbed by 15.94% to -$255.2 million in 2024, then increased by 3.71% to -$245.8 million in 2025, then tumbled by 131.37% to -$568.6 million in 2026.
• Business Quant data shows NKTR's Enterprise Value at -$568.6 million in Q1 2026, -$245.8 million in Q4 2025, and -$270.2 million in Q3 2025.